Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. Neelapu, Sattva; L. Locke, Frederick; L. Bartlett, Nancy; J. Lekakis, Lazaros; B. Miklos, David; A. Jacobson, Caron; Braunschweig, Ira; O. Oluwole, Olalekan; Siddiqi, Tanya; Lin, Yi; M. Timmerman, John; J. Stiff, Patrick; W. Friedberg, Jonathan; W. Flinn, Ian; Goy, André; T. Hill, Brian; R. Smith, Mitchell; Deol, Abhinav; Farooq, Umar; A. McSweeney, Peter; Muñoz, Javier; Avivi, Irit; E. Castro, Januario; R. Westin, Jason; C. Chávez, Julio; Ghobadi, Armin; V. Komanduri, Krishna; Levy, Ronald; D. Jacobsen, Eric; E. Witzig, Thomas; M. Reagan, Patrick; Bot, Adrian; M. Rossi, John; Navale, Lynn; Jiang, Yizhou; Aycock, Jeff; Elias, Meg; Chang, David; Wiezorek, Jeff; Y. Go, William

doi:10.1056/nejmoa1707447

Public

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Published in New England Journal of Medicine • Dec 10, 2017

Authors:

Sattva S. Neelapu

Frederick L. Locke

Nancy L. Bartlett

Abstract

BACKGROUND: In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy. METHODS: anti-CD19 CAR T cells per kilogram of body ...

Subject

Medicine

Internal medicine

Follicular lymphoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!